Other initiatives taken by the FDA to streamline generic drug development include: prioritizing the review of certain generics; publishing a list of off-patent, off-exclusivity branded drugs; and enhancing the efficiency of certain aspects of the submission process for generic drug applicants.
Trump has vowed to tackle rising drug prices since running for office, but his plan spared the pharmaceutical industry from direct government negotiations to control costs, a proposal he endorsed during the 2016 presidential campaign.
Like this story? Subscribe to FierceHealthcare!
Require site neutrality in payment; evaluate the accuracy of national drug spending data; investigate tools that address foreign government licensing or intellectual property theft.
One of the main objectives of the plan is to increase competition in the generic drug market.
"This is a topic the President and I have discussed at great length, and the idea of direct negotiation in Medicare has come up". Democrats also want more transparent calculation of the "true cost" of drug production as a basis for pricing, and they urge an end to tactics created to extend patent protections, such as pay-for-delay deals, patent "evergreening", and the use of FDA Risk Evaluation and Mitigation Strategies (REMS) to block competition.
Create more measures to inform beneficiaries about lower-cost alternatives; Provide better annual information on costs to Part D beneficiaries. Trump promised to take on the "tangled web of special interests" that drive up drug prices, noting the high amount that pharma companies spend on lobbyists to "protect the status quo" and "keep drug prices high". "And we intend to use the full scope of the power contained in this pen on any of these rather than sitting back and waiting for Congress on all items".
Health and Human Services Secretary Alex Azar delivered his speech on drug-pricing reform Monday.
As it stands, the government is being billed sticker price, plus a markup, for drugs under Part B, so Mr. Trump wants to shift them out to fulfill his campaign promise to conduct "smart bidding" on drugs.
"Consumers would have much more balanced information, and companies would have a very different set of incentives for setting their prices", Azar added.
But Trump has since abandoned ideas to lower drug costs he supported during the campaign, including allowing the government's Medicare plan for older Americans to negotiate prices directly with drugmakers, and enabling USA consumers to import lower-cost medicines from other countries.
The federal government now pays providers 6% more than the average price of those medicines. "It will be interesting to see, if we do get there, how you actually have to report that in advertising".
"This is a total rip-off, and we are ending it", Trump said of the so-called "gag rules". These prevent pharmacists from telling consumers when they'd actually save money by paying out of pocket for their medicines. "The last thing we need is open borders for unsafe drugs in search of savings that can not be safely achieved", he said.
HHS is also asking providers to weigh-in on ways they can improve their education and outreach strategies.
"The United States has the safest regulatory system in the world".
"It's not going to lower drug prices", Mitchell says. It's unclear how that would be addressed.
"They're very hard to explain, they're very nuanced", said Walid Gellad, director of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh of the various Medicare proposals.